Ginsenoside Rb1 alleviates lipopolysaccharide-induced inflammation in human dental pulp cells via the PI3K/Akt, NF-κB, and MAPK signalling pathways
- PMID: 38436525
- DOI: 10.1111/iej.14058
Ginsenoside Rb1 alleviates lipopolysaccharide-induced inflammation in human dental pulp cells via the PI3K/Akt, NF-κB, and MAPK signalling pathways
Abstract
Aim: Among numerous constituents of Panax ginseng, a constituent named Ginsenoside Rb1 (G-Rb1) has been studied to diminish inflammation associated with diseases. This study investigated the anti-inflammatory properties of G-Rb1 on human dental pulp cells (hDPCs) exposed to lipopolysaccharide (LPS) and aimed to determine the underlying molecular mechanisms.
Methodology: The KEGG pathway analysis was performed after RNA sequencing in G-Rb1- and LPS-treated hDPCs. Reverse-transcription polymerase chain reaction (RT-PCR) and western blot analysis were used for the assessment of cell adhesion molecules and inflammatory cytokines. Statistical analysis was performed with one-way ANOVA and the Student-Newman-Keuls test.
Results: G-Rb1 did not exhibit any cytotoxicity within the range of concentrations tested. However, it affected the levels of TNF-α, IL-6 and IL-8, as these showed reduced levels with exposure to LPS. Additionally, less mRNA and protein expressions of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) were shown. With the presence of G-Rb1, decreased levels of PI3K/Akt, phosphorylated IκBα and p65 were also observed. Furthermore, phosphorylated ERK and JNK by LPS were diminished within 15, 30 and 60 min of G-Rb1 exposure; however, the expression of non-phosphorylated ERK and JNK remained unchanged.
Conclusions: G-Rb1 suppressed the LPS-induced increase of cell adhesion molecules and inflammatory cytokines, while also inhibiting PI3K/Akt, phosphorylation of NF-κB transcription factors, ERK and JNK of MAPK signalling in hDPCs.
Keywords: MAPK; NF‐kappa B; PI3K/Akt; ginsenoside Rb1; pulpitis.
© 2024 British Endodontic Society. Published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Attele, A.S., Wu, J.A. & Yuan, C.‐S. (1999) Ginseng pharmacology: multiple constituents and multiple actions. Biochemical Pharmacology, 58(11), 1685–1693.
-
- Bindal, P., Ramasamy, T.S., Kasim, N.H.A., Gnanasegaran, N. & Chai, W.L. (2018) Immune responses of human dental pulp stem cells in lipopolysaccharide‐induced microenvironment. Cell Biology International, 42(7), 832–840.
-
- Cartwright, T., Perkins, N.D. & Wilson, C.L. (2016) NFKB1: a suppressor of inflammation, ageing and cancer. The FEBS Journal, 283(10), 1812–1822.
-
- Chang, Y.S., Seo, E.K., Gyllenhaal, C. & Block, K.I. (2003) Panax ginseng: a role in cancer therapy? Integrative Cancer Therapies, 2(1), 13–33.
-
- Chen, S., Li, X., Wang, Y., Mu, P., Chen, C., Huang, P. et al. (2019) Ginsenoside Rb1 attenuates intestinal ischemia/reperfusion‐induced inflammation and oxidative stress via activation of the PI3K/Akt/Nrf2 signaling pathway. Molecular Medicine Reports, 19(5), 3633–3641.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous